TransCode Therapeutics, Inc., (RNAZ): Price and Financial Metrics
RNAZ Price/Volume Stats
| Current price | $0.34 | 52-week high | $18.66 |
| Prev. close | $0.33 | 52-week low | $0.22 |
| Day low | $0.33 | Volume | 203,900 |
| Day high | $0.34 | Avg. volume | 1,238,908 |
| 50-day MA | $0.50 | Dividend yield | N/A |
| 200-day MA | $0.66 | Market Cap | 5.80M |
RNAZ Stock Price Chart Interactive Chart >
TransCode Therapeutics, Inc., (RNAZ) Company Bio
TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs for the treatment of metastatic diseases. The company's lead therapeutic candidate, TTX-MC138, is a preclinical stage product for the treatment of metastatic cancer. Its products in discovery and preclinical stage include MicroRNA-10b, TTX-siPDL1, TTX-siLIN28b, and TTX-RIGA, which focuses on treating various cancers. The company was incorporated in 2016 and is based in Boston, Massachusetts.
RNAZ Price Returns
| 1-mo | -44.26% |
| 3-mo | 24.95% |
| 6-mo | -81.01% |
| 1-year | -96.53% |
| 3-year | -99.98% |
| 5-year | N/A |
| YTD | -94.84% |
| 2023 | -98.78% |
| 2022 | -73.50% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...